CD137 Costimulation Counteracts TGFβ Inhibition of NK-Cell Antitumor Function

Researchers demonstrated that the anti-CD137 agonist urelumab can overcome TGFβ-mediated inhibition of human NK-cell proliferation and antitumor function.